Dealmaking and Industry Outlook: Neurological Disease

Decision Resources
November 2, 2009
37 Pages - SKU: DECR2497060
License type:
Table of Contents Related Reports
The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. The key to future success in this therapy area is a better understanding of the underlying biomarkers, genes, and disease pathways that lead to disease. Pharma companies have scoured the ranks of available drug targets, technologies, and innovation in neurological diseases and have executed a plethora of acquisitions and deals. In this report, we categorize more than 300 deals in the neurological disease industry for a 32-month period including 2007, 2008, and the first eight months of 2009. We assess the neurology market and its major players as well as analyze the deals that companies are executing and the business strategies they are deploying to gain future success.

Questions Answered in This Report
  • Decision Resources Pharmaview analysts forecast that the neurology market will grow to $45.2 billion in 2013. Which pharma companies will be the major players in 2013? What will account for much of the fl ux that will be seen in neurology markets from 2008 to 2013?
  • Analyzing deals opens up a window to a company's business strategies. What do the 340 deals in the neurology industry for 2007, 2008, and the first eight months of 2009 say about pharma companies' strategies in this therapy area? What targets were licensed or optioned? What were the largest deals and who were the most prolific dealmakers? What merger and acquisition strategies were in play?
  • Complications can arise when multiple parties hold rights to the same product and companies get overzealous in their partnering activities? What almost derailed Elan's Tysabri collaboration with Biogen Idec? Why are Johnson & Johnson and Pfizer now partners on an immunotherapy program for AD?
  • Too many small biotechs have too few products of unknown quality to entice investors in a tight money market to invest. How big of a concern is bankruptcy or liquidation for small neurology companies? Which companies have chosen to survive by reverse merger or consolidation?
  • Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates. Why are disease-specific disease foundations so important? What disruptive therapies are in development? What technologies are hot?
  • Researchers must gain a better understanding of disease pathways because interrupting these pathways is the basis of targeted therapeutic intervention. What recent gene discoveries and disease pathways have been discovered? What new therapeutic approaches might supersede existing therapies in development? Scope
  • Expert commentary: Mechanism of action, mitochondria, misfolded proteins, disease pathogenesis, new therapeutic approach, Medivation, Dimebon, Huntington Study Group.
  • Diseases: Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), epilepsy, Huntington's disease (HD), insomnia, migraine, multiple sclerosis (MS), Parkinson's disease (PD), restless legs syndrome (RLS), stroke.
  • Therapy area: Market size, top 25 companies, blockbusters, market share, changing franchises, major products, patent expiry, companies gaining and losing the most sales, new genes, new targets and disease pathways, new therapeutic approaches.
  • Dealmaking: Analysis of more than 300 deals, deal volume, mega-deals valued at more than $1 billion, deals valued at more than $400 million, most-prolific dealmakers, disease-focused nonprofit organizations, dealmaking pitfalls, Big Pharma collaboration, change of control licensing provisions, disease deals, technology deals.
  • Business strategies: Collaborations, codevelopment, co-commercialization, copromotion, strategic alliances, inlicensing, mergers and acquisitions (M&As), divestment, product acquisitions, patent litigation settlements, marketing agreements, marketed product portfolio acquisitions, brand expansion, international expansion, emerging markets, royalty buyouts, manufacturing agreements, options, mega-mergers, targeted acquisitions, activist investors, liquidation, reverse mergers, consolidation, strengthening franchises.
  • Targets: Neuronal nicotinic receptors, orexin receptor, beta-amyloid, neuronal potassium channel openers, autophagy pathway targets, alpha-synuclein, neural glial cell markers, selective adhesion molecules, granulocyte-macrophage colony-stimulating factor, fibroblast growth factor receptor 5, interferon-beta, human alpha-fetoprotein, fibroblast growth factor-2, toll-like receptor 9, myelin basic protein, N-type calcium channels, T-type calcium channels, M1 selective muscarinic agonists, Rasrelated guanosine triphosphate-binding proteins, huntingtin, chloride-gated ion channels, presenilin-1 and -2.
  • Technologies: Immunotherapy, therapeutic vaccines, biologics, biosimilars, stem cell therapy, predictive screening, cell models, new formulations, disease-modifying therapies, peptides, gene therapy, RNA interference, recombinant proteins, biomarkers, glutathione-coated liposomes, nanobodies, Fcfusion proteins, monoclonal antibodies, knock out mice, acetylcholinesterase.
Please note, the PDF e-mail from publisher version of this report is for a global site license.


 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


CNS/Neurology Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!